Asian Pacific Journal of Cancer Prevention

  • 제16권2호
  • /
  • Pages.613-619
  • /
  • 2015
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Predictive Value of Serum Insulin-like Growth Factor-1 in Hepatocellular Carcinoma

  • Elmashad, Nehal (Clinical Oncology, University of Tanta) ;
  • Ibrahim, Wesam Salah (Clinical Pathology, University of Tanta) ;
  • Mayah, Wael Wahid (Tropical Medicine and Infectious Disease, University of Tanta) ;
  • Farouk, Mohamed (Alexandria Clinical Oncology Department, Faculty of Medicine, University of Alexandria, King Abdulaziz University) ;
  • AboAli, Lobna (Tropical Medicine and Infectious Disease, University of Tanta) ;
  • Taha, Atef (Internal Medicine, University of Tanta) ;
  • Elmashad, Wael (Physiology Department, University of Tanta)
  • 발행 : 2015.02.25
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: Hepatocellular carcinoma (HCC) is the commonest primary malignant cancer of the liver in the world. Insulin-like growth factor-1 (IGF-1) levels reflect hepatic function and are inversely correlated with the severity of background chronic liver disease. Objective: This study evaluated whether basal serum IGF-1 levels can predict prognosis of HCC patients according to different risks of disease progression. Materials and Methods: A total of 89 patients with hepatocellular carcinoma (HCC) were recruited in 3 groups: Group I, 30 HCC patients receiving sorafinib; Group II, 30 HCC patients with best supportive care; and Group III include 29 patients undergoing transcatheter arterial chemoembolization (TACE). All patients were investigated for serum levels of AST, ALP, Bb, Cr, BUN, AFP and IGF-I. Results: Patients with disease control had significantly higher baseline IGF-1 levels 210 (185-232.5) ng/mL (p value<0.01) than did patients without disease control. Low basal IGF-1 levels were associated with advanced HCC, such as multiple tumors and advanced stage, and low IGF-1 levels predicted shorter TTP and overall survival in patients treated with TACE. Conclusions: The levels of serum IGF-1, expressed as continuous values, may be helpful for accurately assessing hepatic function and the prognostic stratification of patients with HCC.

키워드

참고문헌

  1. Abdelaziz AO, Elbaz TM, Shousha HI, et al (2014). Survival and prognostic factors for hepatocellular carcinoma: an Egyptian multidisciplinary clinic experience. Asian Pac J Cancer Prev, 15, 3915-20. https://doi.org/10.7314/APJCP.2014.15.9.3915
  2. Beckert S, Farrahi F, Perveen Ghani Q, et al (2006). IGF-I-induced VEGF expression in HUVEC involves phosphorylation and inhibition of poly(ADP-ribose)polymerase. Biochem Biophys Res Commun, 341, 67-72. https://doi.org/10.1016/j.bbrc.2005.12.148
  3. Bid HK, Zhan J, Phelps DA, Kurmasheva RT, Houghton PJ (2012). Potent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody. Mol Cancer Ther, 11, 649-59 https://doi.org/10.1158/1535-7163.MCT-11-0575
  4. Carroll VA, Ashcroft M (2006). Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-lindau function: implications for targeting the HIF pathway. Cancer Res, 66, 6264-70. https://doi.org/10.1158/0008-5472.CAN-05-2519
  5. Catrina SB, Botusan IR, Rantanen A, et al (2006): Hypoxiainducible factor-1alpha and hypoxia-inducible factor-2alpha are expressed in kaposi sarcoma and modulated by insulinlike growth factor-I. Clin Cancer Res, 12, 4506-14. https://doi.org/10.1158/1078-0432.CCR-05-2473
  6. Conchillo M, de Knegt RJ, Payeras M, et al (2005) Insulinlike growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: results of a pilot randomized controlled clinical trial. J Hepatol, 43, 630-6. https://doi.org/10.1016/j.jhep.2005.03.025
  7. De Meyts P (2004). Insulin and its receptor: structure, function and evolution. Bioessays, 26, 1351-62. https://doi.org/10.1002/bies.20151
  8. Dong MQ, Venable JD, Au N, et al (2007). Quantitative mass spectrometry identifies insulin signaling targets in C. Elegans. Science, 317, 660-3. https://doi.org/10.1126/science.1139952
  9. Gariboldi MB, Ravizza R, Monti E (2010). The IGFR1 inhibitor NVP-AEW541 disrupts a pro-survival and pro-angiogenic IGF-STAT3-HIF1 pathway in human glioblastoma cells. Biochem Pharmacol, 80, 455-62. https://doi.org/10.1016/j.bcp.2010.05.011
  10. Hoppener JW, de Pagter-Holthuizen P, Geurts van Kessel AH, et al (1985). The human gene encoding insulin-like growth factor I is located on chromosome 12. Hum Genet, 69, 157-60. https://doi.org/10.1007/BF00293288
  11. Jansen M, van Schaik FM, Ricker AT, et al (1983). Sequence of cDNA encoding human insulin-like growth factor I precursor. Nature, 306, 609-11. https://doi.org/10.1038/306609a0
  12. Jones JI, Clemmons DR (1995). Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev, 16, 3-34.
  13. Kaseb AO, Abbruzzese JL, Vauthey JN, et al (2011a). I-CLIP: improved stratification of advanced hepatocellular carcinoma patients by integrating plasma IGF-1 into CLIP score. Oncology, 80, 373-81. https://doi.org/10.1159/000329040
  14. Kaseb AO, Morris JS, Hassan MM, et al (2011b). Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. J Clin Oncol, 29, 3892-9. https://doi.org/10.1200/JCO.2011.36.0636
  15. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE (2000). The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev, 21, 215-44. https://doi.org/10.1210/edrv.21.3.0399
  16. Lorenzo-Zuniga V, Bartoli R, Masnou H, et al (2007). Serum concentrations of insulin-like growth factor-I (igf-I) as a marker of liver fibrosis in patients with chronic hepatitis C. Dig Dis Sci, 52, 3245-50. https://doi.org/10.1007/s10620-006-9437-1
  17. Maki RG (2010). Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer. J Clin Oncol, 28, 4985-95. https://doi.org/10.1200/JCO.2009.27.5040
  18. Mazziotti G, Sorvillo F, Morisco F, et al (2002). Serum insulinlike growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a prospective study. Cancer, 95, 2539-45. https://doi.org/10.1002/cncr.11002
  19. Miura Y, Kato H, Noguchi T (1992). "Effect of dietary proteins on insulin like growth factor-1 (IGF-1) messenger ribonucleic acid content in rat liver". Br J Nutr, 67, 257-65. https://doi.org/10.1079/BJN19920029
  20. Moser C, Schachtschneider P, Lang SA, et al (2008). Inhibition of insulin-like growth factor-I receptor (IGFIR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis. Eur J Cancer, 44, 1577-86. https://doi.org/10.1016/j.ejca.2008.04.003
  21. Ng IO, Lee JM, Srivastava G, Ng M (1998). Expression of insulin-like growth factor II mRNA in hepatocellular carcinoma. J Gastroenterol Hepatol, 13, 152-7. https://doi.org/10.1111/j.1440-1746.1998.tb00630.x
  22. Page EL, Robitaille GA, Pouyssegur J, Richard DE (2002). Induction of hypoxia-inducible factor-1alpha by transcriptional and translational mechanisms. J Biol Chem, 277, 48403-9. https://doi.org/10.1074/jbc.M209114200
  23. Pollak M, Schernhammer ES, Hankinson SE (2004). Insulin-like growth factors and neoplasia. Nature Rev Cancer, 4, 505-18. https://doi.org/10.1038/nrc1387
  24. Pollak M (2008). Insulin and insulin-like growth factor signalling in neoplasia. Nature Rev Cancer, 8, 915-28. https://doi.org/10.1038/nrc2536
  25. Qian J, Yao D, Dong Z, et al (2010). Characteristics of hepatic igf-ii expression and monitored levels of circulating IGF-II mRNA in metastasis of hepatocellular carcinoma. Am J Clin Pathol, 134, 799-806. https://doi.org/10.1309/AJCPTFDSE2V3LCZP
  26. Reinmuth N, Liu W, Fan F, et al (2002). Blockade of insulinlike growth factor I receptor function inhibits growth and angiogenesis of colon cancer. Clin Cancer Res, 8, 3259-69.
  27. Sanai FM, Sobki S, Bzeizi KI, et al (2010). Assessment of alphafetoprotein in the diagnosis of hepatocellular carcinoma in Middle Eastern patients. Dig Dis Sci, 55, 3568-75. https://doi.org/10.1007/s10620-010-1201-x
  28. SCH717454 is reversed by IGF-2 (2012). Mol Cancer Ther, 11, 649-59. https://doi.org/10.1158/1535-7163.MCT-11-0575
  29. Shao YY, Huang CC, Lin SD, Hsu CH, Cheng AL (2012). Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy. Clin Cancer Res, 18, 3992-7. https://doi.org/10.1158/1078-0432.CCR-11-2853
  30. Shaw RJ, Lamia KA, Vasquez D, et al (2005). The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science, 310, 1642-6. https://doi.org/10.1126/science.1120781
  31. Sobrevals L, Rodriguez C, Romero-Trevejo JL, Gondi G, Monreal I, et al. (2010). Insulin-like growth factor I gene transfer to cirrhotic liver induces fibrolysis and reduces fibrogenesis leading to cirrhosis reversion in rats. Hepatology, 51, 912-21.
  32. Steiner DF, Chan SJ, Welsh JM, Kwok SC (1985): Structure and evolution of the insulin gene. Annu Rev Genet, 19, 463-84. https://doi.org/10.1146/annurev.ge.19.120185.002335
  33. Su CH, Lin Y, Cai L (2013). Genetic factors, viral infection, other factors and liver cancer: an update on current progress. Asian Pac J Cancer Prev, 14, 4953-60. https://doi.org/10.7314/APJCP.2013.14.9.4953
  34. Sutton KM, Hayat S, Chau NM, et al (2007). Selective inhibition of MEK1/2 reveals a differential requirement for ERK1/2 signalling in the regulation of HIF-1 in response to hypoxia and IGF-1. Oncogene, 26, 3920-9. https://doi.org/10.1038/sj.onc.1210168
  35. Toyoshima Y, Monson C, Duan C, Wu Y, Gao C, Yakar S, Sadler KC, LeRoith D (2008). The role of insulin receptor signaling in zebrafish embryogenesis. Endocrinology, 149, 5996-6005. https://doi.org/10.1210/en.2008-0329
  36. Treiber G, Wex T, Rocken C, Fostitsch P, Malfertheiner P (2006). Impact of biomarkers on disease survival and progression in patients treated with octreotide for advanced hepatocellular carcinoma. J Cancer Res Clin Oncol, 132, 699-708. https://doi.org/10.1007/s00432-006-0118-4
  37. Yang JD, Nakamura I, Roberts LR (2011). The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Sem Cancer Biol, 21, 35-43. https://doi.org/10.1016/j.semcancer.2010.10.007
  38. Zekri AR, Hassan ZK, Bahnassy AA, et al (2012). Molecular prognostic profile of Egyptian HCC cases infected with hepatitis C virus. Asian Pac J Cancer Prev, 13, 5433-8. https://doi.org/10.7314/APJCP.2012.13.11.5433
  39. Zhou L, Liu C, Meng FD, et al (2012). Long-term prognosis in hepatocellular carcinoma patients after hepatectomy. Asian Pac J Cancer Prev, 13, 483-6. https://doi.org/10.7314/APJCP.2012.13.2.483

피인용 문헌

  1. Insulin-Like Growth Factor (IGF) System in Liver Diseases vol.19, pp.5, 2018, https://doi.org/10.3390/ijms19051308